Product details of Bicozin Tablet 30’s, 1 Pot [Thiamine HCl, Riboflavin, Nicotinamide, Pyridoxine]
- Quantity number indicates 1 bottle
- 30 pcs in one bottle.
- Indicated for:-Treatment and prevention of B-vitamins and Zinc deficiencies.
Bicozin® Vitamin B Complex and Zinc Vitamin B and B-complex (Vitamins and Minerals)
Indication: Treatment and prevention of B-vitamins and Zinc deficiencies.
Adults: 10 ml (2 teaspoonfuls) 2 to 3 times daily,
Children: 10 ml (2 teaspoonfuls) 1 to 3 times daily, Infants: 5 ml (1 teaspoonful) 1 to 2 times daily.
Preparation: Thiamine Hydrochloride 5 mg, Riboflavin 2 mg, Pyridoxine Hydrochloride 2 mg, Nicotinamide 20 mg and elemental Zinc 10 mg/5 ml Syrup. Thiamine Mononitrate 5 mg, Riboflavin 2 mg, Pyridoxine Hydrochloride 2 mg, Nicotinamide 20 mg & elemental Zinc 10 mg/Tablet.
If your delivery address is within Dhaka city, products will be delivered by within 2-5 business days. If it is outside Dhaka, it will take 5-7 business days.
Note: Product delivery duration may vary due to product availability in stock.
Rabeprazole Sodium is an antiulcerant drug in the class of Proton Pump Inhibitors. Rabeprazole Sodium is a substituted benzimidazole which suppresses gastric acid secretion by inhibiting the gastric H+/K+-ATPase enzyme at the secretory surface of the gastric parietal cell. It is an enteric coated tablet, because of its coated formulation it is highly stable in stomach and because of higher pKa value of Rabeprazole Sodium it provides faster onset of action. It blocks the final step of gastric acid secretion. After oral administration of 20 mg, Rabeprazole is absorbed and can be detected in plasma by 1 hour. The effects of food on the absorption of Rabeprazole have not been evaluated. Rabeprazole is 96.3% bound to human plasma proteins. Rabeprazole is primarily metabolized in the liver by Cytochrome P-450 3A (Sulphone metabolite) and 2C19 (Desmethyl Rabeprazole). Following a single 20 mg oral dose of Rabeprazole, approximately 90% of the drug is eliminated in the urine.The remainder of the dose is excreted in the feaces.Dosage & Administration Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD): 20 mg to be taken once daily for 4 to 8 weeks. For those patients who have not healed after 8 weeks of treatment, an additional 8 week course may be considered. Maintenance of Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD Maintenance): The recommended adult oral dose is 20 mg once daily. Treatment of Symptomatic Gastroesophageal Reflux Disease (GERD):The recommended adult oral dose is 20 mg once daily for 4 weeks. If symptoms do not resolve completely after 4 weeks, an additional course of treatment may be considered. Healing of Duodenal Ulcers:The recommended adult oral dose is 20 mg once daily after the morning meal for a period up to four weeks. Most patients with duodenal ulcer heal within four weeks. A few patients may require additional therapy to achieve healing. Helicobacter pylori Eradication: To Reduce the Risk of Duodenal Ulcer Recurrence- Rabeprazole Sodium 20 mg Twice Daily for 7 Days Amoxicillin 1000 mg Twice Daily for 7 Days Clarithromycin 500 mg Twice Daily for 7 Days All three medications should be taken twice daily with the morning and evening meals. It is important that patients comply with the full 7-day regimen. Treatment of Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome: The dosage of Rabeprazole Sodium in patients with pathologic hypersecretory conditions varies with the individual patient. The recommended adult oral starting dose is 60 mg once a day. Doses should be adjusted to individual patient needs and should continue for as long as clinically indicated. Some patients may require divided doses. Doses up to 100 mg QD and 60 mg BID have been administered. Some patients with Zollinger-Ellision syndrome have been treated continuously with Rabeprazole Sodium for up to one year. Interaction Rabeprazole is metabolized by the Cytochrome P-450 (CYP-450) drug metabolizing enzyme system. Rabeprazole does not have clinically significant interactions with other drugs metabolized by the CYP-450 system,such as Warfarin and Theophylline given as single oral dose, Diazepam as a single intravenous dose, and Phenytoin given as a single intravenous dose. In normal subjects, co-administration of Rabeprazole 20 mg QD resulted in an approximately 30% decrease in the bioavailability of Ketoconazole and increase in the AUC and Cmax for digoxin of 90% and 29% respectively. Contraindications Rabeprazole Sodium is contraindicated in patient with known hypersensitivity to Rabeprazole or to any component in the product. Side Effects Rabeprazole Sodium may sometimes cause headache, diarrhoea, abdominal pain, vomiting, constipation, dry mouth, increased or decreased appetite, muscle pain, drowsiness and dizziness. Pregnancy & Lactation Rabeprazole is FDA Pregnancy Category B. No data is available on administration of Rabeprazole to pregnant women. However this drug should be used during pregnancy, only if clearly needed. There are no data on the excretion of Rabeprazole into the breast milk. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the benefit of the drug to the mother. Precautions Administration of Rabeprazole Sodium to patients with mild to moderate liver impairment resulted in increased exposure and decreased elimination. Caution should be exercised in patients with severe hepatic impairment. Overdose Effects There has been no experience with large overdoses with Rabeprazole. No specific antidote for Rabeprazole is known. Rabeprazole is extensively protein bound and is not readily dialyzable. In the event of overdosage, treatment should be symptomatic and supportive. Use in Special Population
Use in pediatric patients: The safety and effectiveness of Rabeprazole in pediatric patients have not been established. Storage Conditions Store below 25°C, protected from light and moisture. Keep all medicines out of the reach of the children.
COMPOSITION Tablet: Each tablet containsDried Aluminium Hydroxide Gel BP 425.53 mg (Al2O3, 47% minimum) Magnesium Hydroxide BP 400 mg Simethicone USP 30 mg Suspension: Each 5 ml contains - Aluminium Oxide 200 mg (Equivalent amount of Aluminium Hydroxide Gel USP) Magnesium Hydroxide 400 mg (Equivalent amount of Magnesium Hydroxide Paste USP) Simethicone USP 30 mgPHARMACOLOGY Entacyd® Plus is the mixture of non-systemic acid neutralizing substances and antiflatulent. This preparation offers reliability as well as long action. Aluminium Hydroxide and Magnesium Hydroxide induce the relief of ulcer by neutralizing gastric acid secreted from parietal cells of the stomach. The clinical use of simethicone is based on its antifoam properties. Simethicone spreads on the surface of aqueous liquids, forming a film of low surface tension and causing collapse of foam bubbles. Simethicone repeatedly allows mucous surrounded gas bubbles in the GI tract to coalesce and be expelled. Entacyd® plus is used in the treatment of flatulence and meteorism for the elimination of gas, air or foam from the gastro-intestinal tract prior to radiography and for the relief of abdominal distension and dyspepsia. Simethicone is physiologically inert; it does not appeared to be absorbed from the GI tract to interfere with gastric secretion or absorption of nutrients. Following oral administration, the drug is excreted unchanged in the feces. INDICATION Entacyd® Plus is indicated for symptomatic relief of hyperacidity associated with the peptic ulcer, gastritis, peptic oesophagitis, gastric hyperacidity, heartburn, sour stomach or hiatus hernia. It is effective in the prevention of stress ulceration and GI bleeding. It acts as an antiflatulent to alleviate the symptoms of gas including post operative gas pain. Entacyd® Plus rapidly Aluminium Hydroxide, Magnesium Hydroxide, Simethicone Antacid, Antiulcerants Entacyd® Plus ALIMENTARY PREPARATIONS relieves acid pain, disperses gastric foam and facilitates eructation of gas and air. DOSAGE AND ADMINISTRATION Tablet: 1-2 tablets 1-3 hours after meal and at bed time or as directed by the physician. Suspension: 1-2 teaspoonful 1-3 hours after meal and at bedtime or as directed by the physician. CONTRAINDICATION AND PRECAUTION
Entacyd® Plus should not be administered in patients with renal failure or hypophosphataemia or in those who are severely debilitated. It is also contraindicated in alkalosis and hypermagnesaemia, where abdominal distention may be due to partial or complete intestinal obstruction. Entacyd® Plus should be used with caution in patients with kidney disease.SIDE EFFECT Gastrointestinal side effects are uncommon. Occasionally, if excessive amount is consumed, diarrhea, constipation or regurgitation may occur. DRUG INTERACTION All antacids may increase or decrease the rate and/or extent of absorption of concomitantly administered oral drugs. Antacids decrease the bioavailability of theophyline, tetracycline, quinolone antibiotics, isoniazide, ketoconazole, ethambutol, some antimuscarinic drugs, benzodiazepines, phenothiazines, ranitidine, indomethacine, nitrofurantoin, fluoride, phosphate, propanolol, atenolol, digoxins, vitamins etc. Antacids increase the bioavailability of some drugs; e.g. sulphonamides, levodopa, valproic acid, enteric coated aspirin etc. USE IN PREGNANCY It is advised to avoid antacid preparations in the first trimester of pregnancy. STORAGE CONDITION Store in cool and dry place, out of reach of children. HOW SUPPLIED Entacyd® Plus tablet: Box containing 20 x 10 tablets in blister pack. Entacyd® Plus suspension: Bottle containing 200 ml suspension.